A multi-center, double-blind, placebo-controlled, parallel-group study to establish proof-of-concept and explore the efficacy of different doses of ACT-129968 in adult patients with partly controlled asthma.

Trial Profile

A multi-center, double-blind, placebo-controlled, parallel-group study to establish proof-of-concept and explore the efficacy of different doses of ACT-129968 in adult patients with partly controlled asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Setipiprant (Primary)
  • Indications Asthma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CONTROL
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 05 Apr 2012 Status changed from active, no longer recruiting to completed.
    • 02 Apr 2012 Primary endpoint 'Forced-expiratory-volume-in-1-second' has not been met.
    • 24 Mar 2012 Additional locations added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top